Amyris (AMRS) Receives a Buy from H.C. Wainwright


H.C. Wainwright analyst Amit Dayal maintained a Buy rating on Amyris (AMRS) yesterday and set a price target of $11.00. The company’s shares closed last Tuesday at $3.41.

According to TipRanks.com, Dayal is a 5-star analyst with an average return of 17.3% and a 47.7% success rate. Dayal covers the Industrial Goods sector, focusing on stocks such as Ballard Power Systems, Westport Fuel Systems, and Orion Energy Systems.

Currently, the analyst consensus on Amyris is a Moderate Buy with an average price target of $10.00.

See today’s analyst top recommended stocks >>

Based on Amyris’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $30.01 million and GAAP net loss of $110 million. In comparison, last year the company earned revenue of $62.69 million and had a GAAP net loss of $38.09 million.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMRS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amyris, Inc. engages in the provision of bioscience solutions. It offers its products to health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Read More on AMRS:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts